Molecular and Cellular Biology, August 2001, p. 5031-5040, Vol. 21, No. 15
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.15.5031-5040.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Department of Genetics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02 106 Warsaw, Poland1; Department of Biochemistry, University of Louisville Medical Center, Louisville, Kentucky 402923; Department of Biochemistry and Molecular Biology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania 170334; and Service de Biochimie et de Génétique Moléculaire, CEA/Saclay, F-91191 Gif-sur-Yvette Cedex, France2
Received 1 February 2001/Returned for modification 2 March 2001/Accepted 24 April 2001
| |
ABSTRACT |
|---|
|
|
|---|
Although yeast RNA polymerase III (Pol III) and the auxiliary factors TFIIIC and TFIIIB are well characterized, the mechanisms of class III gene regulation are poorly understood. Previous studies identified MAF1, a gene that affects tRNA suppressor efficiency and interacts genetically with Pol III. We show here that tRNA levels are elevated in maf1 mutant cells. In keeping with the higher levels of tRNA observed in vivo, the in vitro rate of Pol III RNA synthesis is significantly increased in maf1 cell extracts. Mutations in the RPC160 gene encoding the largest subunit of Pol III which reduce tRNA levels were identified as suppressors of the maf1 growth defect. Interestingly, Maf1p is located in the nucleus and coimmunopurifies with epitope-tagged RNA Pol III. These results indicate that Maf1p acts as a negative effector of Pol III synthesis. This potential regulator of Pol III transcription is likely conserved since orthologs of Maf1p are present in other eukaryotes, including humans.
| |
INTRODUCTION |
|---|
|
|
|---|
The yeast RNA polymerase III (Pol III) transcription system is well characterized. Small untranslated RNAs with essential housekeeping functions, such as tRNAs, 5S rRNA, or the U6 small nuclear RNA (snRNA) that is required for mRNA splicing, are synthesized by Pol III with the help of two general auxiliary factors, TFIIIC and TFIIIB. The large TFIIIC factor (six subunits) binds to the DNA promoter elements and assembles the initiation factor TFIIIB (three components) upstream of the start site. Once TFIIIB is in position, it recruits the Pol III enzyme (17 subunits) and directs accurate and multiple rounds of transcription. All of the polypeptide components of the Pol III apparatus (~1,500 kDa) have been characterized and found to be essential for cell viability (8, 23). The identification of the components of the Pol III system has facilitated the description of a cascade of protein-protein interactions that leads to the recruitment of the Pol III enzyme (reviewed in reference 55).
Detailed knowledge of the yeast Pol III transcription system contrasts with the limited information available on the control of class III gene expression in yeast. Cellular tRNA levels respond to cell growth rate (48, 49), to a nutritional upshift (27, 48) or to nitrogen starvation (36) but only modestly to amino acid starvation (41). Finally, Pol III transcription is repressed in secretion-defective cells (30). Although the mechanism of repression is not clear, it does involve activation of the cell integrity pathway (30). The effect of growth conditions on Pol III transcription is well mimicked in vitro with whole-cell extracts (11, 39). tRNA synthesis is downregulated in dense cell cultures approaching stationary phase, a result due essentially to reduced TFIIIB activity. The TFIIIB component Brf/TFIIIB70 was found to be the limiting factor in extracts from such cells (39). However, the occupancy of the TFIIIB binding site on the SUP53 gene encoding tRNALeu does not decrease in stationary-phase cells. Rather, in vivo footprinting data suggest reduced promoter occupancy by Pol III (25).
In higher eukaryotic cells, Pol III transcription responds to growth rate, developmental phase, cell cycle position, and a number of pathological conditions (reviewed in reference 55). The regulation operates principally at the level of TFIIIB and TFIIIC (17, 20, 42, 46, 52). The tumor suppressors Rb and p53 inhibit TFIIIB (9, 10, 28, 53). Therefore, it is likely that the control of Pol III transcription rate is important in restraining tumor cell proliferation (54). No equivalent negative regulator of Pol III transcription has been found in yeast.
Genes controlling tRNA synthesis in yeast can be identified by nonsense suppression approaches (22). One candidate for such a gene is Saccharomyces cerevisiae MAF1. It was originally identified by the isolation of maf1-1 as a temperature-sensitive mutation that decreases the efficiency of SUP11 (tRNA Tyr/UAA) suppression (34). A search for multicopy suppressors of maf1-1 revealed an intriguing genetic interaction between MAF1 and RPC160, the gene encoding the largest subunit of the RNA Pol III, C160. RPC160 genes with 3' deletions in their open reading frame suppress the maf1-1 phenotypes when overexpressed (6).
In the present work, we show that tRNA levels are elevated in maf1-1 cells and that spontaneous mutations in RPC160 which reduce tRNA levels also suppress the growth phenotype associated with maf1-1. maf1-1 cell extracts support increased levels of Pol III transcription in vitro compared to wild-type cells. Further, we show that Maf1p is a nuclear protein that physically interacts with RNA Pol III. Therefore, Maf1p appears to be a negative effector of Pol III activity, potentially regulating the level of cellular tRNA in response to external signals. A database search revealed that a variety of organisms have sequences similar to Maf1p, suggesting that this type of Pol III regulation may not be limited to yeast.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Media.
The following media were used for growth of yeast:
YPD (2% glucose, 2% peptone, 1% yeast extract), YPGly (2% glycerol,
2% peptone, 1% yeast extract), and W0 (2% glucose, 0.67% yeast
nitrogen base without amino acids). W0
ura, W0
trp, and W0
leu
contained 20 µg of the amino acids per ml required for growth except
for the single amino acid as indicated. 5-Fluoroorotic acid (5-FOA) medium was prepared as described previously (4).
Sporulation medium (SP1) contains 0.25% yeast extract, 0.1% glucose,
and 0.98% potassium acetate. Solid media contained 2% agar. All
reagents used for media were Difco products.
Strains and plasmids.
The strains used in this study are
listed in Table 1. MT6-7, the
maf1-1 mutant, was derived by ethyl methanesulfonate
mutagenesis of T8-1D (34). The MAF1 gene was
disrupted by replacing the internal NheI-HpaI
fragment with the URA3 cassette, as described previously
(6). KC3-4D, designated as
maf1, was derived
by sporulation of 4A × 11D diploid heterozygous
disruption-deletion of the MAF1 gene. R16 and K2 were
selected as spontaneous revertants of maf1-1 in MB123-2C and
maf1 in KC3-4D, respectively. In MW671-HA the chromosomal
copy of RPC160 is deleted, and C160 is provided by pC160-240
(TRP1 CEN4 HA-RPC160) plasmid carrying the RPC160 gene hemagglutinin HA-tagged at the 5' end (14). DNA
coding for 13 repeats of the myc epitope was inserted just before the stop codon in the endogenous MAF1 in MW671-HA by a PCR-based
gene deletion and modification system (31).
|
trp and 5-FOA medium but can grow on W0
ura media
because it only contains pC160-6 (URA3 CEN4 RPC160) and
produces a tagged Maf1p-myc and nontagged C160.
To construct a gene encoding HA tagged MAF1, a
ClaI site was created just upstream of the stop codon of the
MAF1 open reading frame employing an oligonucleotide,
CTGTATCGATTCTTCTTGATCTG, to allow in-frame ligation of the
sequence coding for the HA epitope from pYeFH2 (12). This
construct was cut with NotI to insert the 110-bp
NotI-NotI fragment from pBF30 that encodes a
triple HA epitope (47). The EcoRI fragment,
containing MAF1 with its own promoter and four HAs at the 3'
end, was subcloned into YCp111 (16), giving YCpMAF-4HA
(URA3 CEN4 MAF1-HA).
Identification of maf1-1 mutation. Two overlapping fragments of the maf1-1 allele and control wild-type MAF1 were amplified by PCR using specific primers, AmpliTaq DNA polymerase (Perkin-Elmer), and genomic DNA prepared from strains MT6-7 and T8-1D. The primer sequences were CGAGGATCCGATGAAATTTATTGATGAGCTAGAT, TGCTGTACCAGAACTG, GAGGATAAGAAGAAGGAG, and CGCGGATCCTACTGTAGGGATTCTTC. The PCR products were sequenced with the same primers in an automatic sequencer ABI PRISM (Perkin-Elmer).
Immunofluorescence. Immunofluorescence microscopy of Maf1p-HA protein was performed as described previously (37). Mouse 16B12 anti-HA (BabCo) was used in a 1:750 dilution as the primary antibody, and goat anti-mouse Cy3 (Jackson Immunoresearch Laboratories, West Grove, Pa.) at 1:250 dilution was used as the secondary antibody. Cells were stained with DAPI (4',6'-diamidino-2-phenylindole) at a final concentration of 4 µg/ml for 2 min. Samples were viewed at ×600 magnification on a Nikon Microphot-S.A. microscope equipped with filters for epifluorescence. Images were captured and saved electronically.
Preparation of total RNA and Northern analysis.
Cells were
grown in liquid YPD or YPGly at 30°C to log phase
(A600 = ca 0.8) and then shifted to a
restrictive temperature for 2.5 h. Total RNA was isolated from
cells disrupted with glass beads by phenol extraction using LETS buffer
(0.1 M LiCl; 0.01 M Na2EDTA; 0.01 M Tris-Cl, pH 7.4; 0.2%
sodium dodecyl sulfate [SDS]) (26). A total of 10 µg
of each RNA sample was resolved by electrophoresis in 7 M urea, 6%
polyacrylamide gel electrophoresis (PAGE), or 1.2% Tris-borate-EDTA
(TBE) agarose gels. The RNAs were transferred from agarose gel to a
Zeta-probe membrane (Bio-Rad) with 10× SSC (1× SSC is 0.15 M NaCl
plus 0.015 M sodium citrate) by capillary action. For quantitative
studies, slot blots were prepared. The membrane was prehybridized in
4× SSC-20 mM EDTA-0.5% SDS-0.1 mg of denatured salmon sperm DNA
per ml, and the RNA was hybridized at 37°C in the same solution with
oligonucleotide probes labeled with [
-32P]ATP and T4
polynucleotide kinase. The probes were as follows: 5'-GCCATCTCCTAGAATCGAACCAGG-3', complementary to
tRNAHis; 5'-GGTAAATTACAGTCTTGCG-3',
complementary to tRNATyr;
5'-CAGTTGATCGGACGGGAACA-3', complementary to 5S rRNA; and
5'-GGATTGCGGACCAAGCTAA-3', complementary to U3 snRNA. After
hybridization, blots were washed 15 min in 6× SSC at room temperature,
exposed to film, or exposed to a phosphorimager plate. RNA was
quantified using the laser densitometer GelScan XL (Pharmacia).
Arithmetic means and standard deviations of tRNA levels, corrected for
snRNA U3 levels, obtained for at least three independent blots are presented.
In vivo labeling of RNA. Cells were grown in low-phosphate YPD at 30°C to an optical density at 600 nm of 0.8 and then pulse-labeled using 150 µCi of carrier-free [32P]orthophosphate per ml of culture. After 5 min, unlabeled potassium phosphate was added to a final concentration of 0.8 M. The cell culture was further incubated for 15 min and then centrifuged and frozen prior to the preparation of total RNA. Labeled RNA (5 µg) was separated on a 7 M urea-6% PAGE gel. Gels were stained with ethidium bromide, dried, and exposed to a phosphor storage plate or autoradiographed. Quantitative analysis of RNA bands was done as described above.
In vitro transcription.
Wild-type (T8-1D) and
maf1-1 mutant (MT6-7) cell extracts were prepared in
parallel essentially as follows. First, 6 to 8 g of cells grown in
YPD at 30°C was collected in early stationary phase
(A600 = ca. 2.0), washed two times with
solubilization buffer (200 mM Tris acetate, pH 8.0; 10 mM magnesium
acetate; 10 mM
-mercaptoethanol; 10% glycerol), resuspended at 1 ml/g (wet weight) of cells in buffer A800 (180 mM Tris acetate, pH 8.0;
9 mM magnesium acetate; 800 mM ammonium sulfate; 10 mM
-mercaptoethanol; 10% glycerol, 2.5 mM phenylmethylsulfonyl
fluoride; Complete protease inhibitor [Roche]), frozen at
70°C in
dry ice and ethanol, and disrupted in an Eaton press. The homogenized
paste was resuspended at 0.5 ml/g (wet weight) of cells in buffer A400
(same as buffer A800 but with 400 mM ammonium sulfate), and clarified
by centrifugation at 20,000 rpm for 10 min ( Beckman roter JA20). The
extract was then diluted with 1 ml of buffer A400/g (wet weight) of
cells and centrifuged at 40,000 rpm for 150 min in a Beckman 45Ti
ultracentrifuge rotor. The whole supernatant was collected, taking care
to avoid the flaky white layer at the top of the tubes, and dialyzed
for 3 h against 1 liter of transcription buffer (20 mM Tris
acetate, pH 8.0; 8 mM magnesium acetate; 25 mM ammonium sulfate; 0.5 mM dithiothreitol [DTT]; 10% glycerol, 1 mM phenylmethylsulfonyl fluoride; 175 mM potassium glutamate). Insoluble material was removed
by low-speed centrifugation.
-32P]UTP (400 Ci/mmol;
Amersham); 8 U of RNasin inhibitor (Promega), 40 ng of DNA per
template; and protein crude extract. Each transcription experiment was
carried out with two DNA templates: a mini-35S rRNA gene
(35) and a Pol III gene. The transcription extract (65 µg of protein) was preincubated with the DNA templates for 60 min at
25°C in the transcription mixture in the absence of nucleotides.
Transcription was initiated by the addition of the nucleotides, allowed
to proceed for 15 min at 25°C, and then stopped by the addition of 60 µl of 30 mM EDTA containing E. coli tRNA (800 µg/ml).
Nucleic acids were extracted once with phenol-chloroform-isoamyl alcohol (25:24:1) and, after addition of 200 µl of 2.5 M ammonium acetate, the RNA was precipitated with 2.5 volumes of ethanol and
analyzed on a 7 M urea-6% PAGE gel. Gels were exposed to a PhosphorImager plate (Molecular Dynamics). RNA was quantified using
ImageQuant software v.1.1. The arithmetic means and standard deviations
of Pol III transcripts levels, corrected for mini-35S rRNA levels, were
derived from five independent cell cultures per strain.
Immunopurification experiments.
Immunoprecipitation
reactions were performed with cellular extracts (30 µg/µl of
protein in a 50-µl reaction volume) in extraction buffer (HEPES [pH
7.5], 50 mM; EDTA, 0.5 mM; CH3COOK, 500 mM; DTT, 1 mM;
glycerol, 10%). The reactions were incubated while being agitated at
1,000 rpm in the presence of Dynal PanMouse immunoglobulin G beads
(Dynal A.S.) preloaded with either
-myc or
-HA antibody.
Incubation was for 3 h at 4°C. Routinely, 2 µg of antibody was
incubated with 20 µl of the beads (4 × 108/ml).
Beads were recovered by use of a magnet and washed with extraction
buffer. The proteins bound to the beads were separated on SDS-8% PAGE
gels and analyzed by immunoblotting. The protein concentration was
estimated by use of a Bio-Rad protein assay using bovine serum albumin
as a standard.
Immunoblotting. Proteins separated by SDS-8% PAGE were transferred electrophoretically to nitrocellulose membranes. After incubation with a specific antibody as indicated, immune complexes were visualized with anti-mouse or anti-rabbit monoclonal antibody coupled to horseradish peroxidase (Amersham Life Sciences). The monoclonal antibodies 9E10 against myc and 12CA5 against HA were applied.
Sequence homology searches. S. cerevisiae Maf1p (GI:642810) was searched against several databases using the BLAST (1) server at The National Center for Biotechnology Information (NCBI). Similar proteins were exhaustively searched against the same databases until all similar proteins were identified. The identified protein sequences were aligned using CLUSTAL X (45) based on the BLOSUM 62 scoring matrix (19). Complete MAF1-like genes were identified in Caenorhabditis elegans (GI:3786409), Candida albicans (Con 5 2883), and Arabidopsis thaliana (GI:7529279). Partial genomic sequences resembling MAF1 were identified in the following organisms: Plasmodium falciparum (AL035476), Cryptosporidium parvum (AQ522040, B83774, and G35235), and Schizosaccharomyces pombe (GI:2388951, GI:2388963, and GI:1507665). Translations of expressed sequence tags (ESTs) from the following organisms appear to be Maf1p homologs: human, AL040071, AA352022, AA179500, AA486502, AA143586, and others; mouse, AA671675, AA066820, AA467315, AA154074, AA042010, and others; rat, AA899627, H34701, H32342, AI172177, and AA817806; zebrafish, AI794541; Drosophila melanogaster, AA142300, AA140704, AI403188, AA539678, and AI109742; Bombyx mori, AU006267; Brugia malayi, AA841076 and AA471615; Arabidopsis thaliana, AL096524, R83973, AI992545, and AA042353; rice, C26657, D24548, C26708, AU030720, and AQ050286; and Saccharum spp., AA525694.
| |
RESULTS |
|---|
|
|
|---|
Maf1p is a nuclear protein conserved from yeast to humans.
Yeast MAF1 gene (6) encodes a hydrophilic
protein of 395 amino acids rich in serine and asparagine residues with
a predicted molecular mass of 44.7 kDa. Comparison of the Maf1p
sequence with multiple databases using the BLAST server at the NCBI
revealed potential orthologs in human, animals, plants, and lower
eukaryotes (Fig. 1). No potential
prokaryotic orthologs were identified. The eukaryotic proteins
identified share three regions of high similarity that are shown in
Fig. 1 (labeled regions A, B, and C). Within these regions signature
sequences for this protein family can be identified (PDYDFS
and WSfnYFFYNkklKR). These motifs have not been
previously reported in the PROSITE database (21). Interestingly, in the majority of Maf1p homologs, the second motif includes a putative nuclear targeting signal. The PSORT program found
two possible nuclear targeting signals in S. cerevisiae Maf1p: KRRK (position 204) and a double signal RKRK-KRKR
(positions 327 and 328).
|
maf1 disruption (KC3-4D). In strains
containing YCpMAF-4HA, the anti-HA antibody revealed a protein of about
49 kDa that corresponded to the size expected for HA-tagged Maf1p (not
shown). When
maf1 cells transformed with YCpMAF-4HA were
inspected by indirect immunofluorescence microscopy, a specific signal
derived from epitope-tagged Maf1p was detected in the nucleus (Fig.
2), while the cytoplasmic background was
the same as in the negative control. Therefore, we concluded that Maf1p
is a nuclear protein.
|
Mutations in RPC160 suppress the maf1
defects.
To gain a better understanding of Maf1p function, we
searched for second-site suppressors of maf1-1 and
spontaneous bypass suppressors of a
maf1 disruption.
maf1 mutants are temperature sensitive on nonfermentable
carbon sources (6). We selected for suppressor mutations
that allowed colonies to grow at the restrictive temperature of 37°C
on glycerol-containing medium (YPGly). Three spontaneous revertants of
maf1-1, i.e., R2, R9, and R16, were isolated. R2 and R9 were
obtained from MT6-7, while R16 was obtained from MB123-2C (Fig.
3A). All partially complemented the
antisuppressor phenotype of maf1-1 (not shown). In a
parallel screen, one revertant, K2, was isolated in
maf1
KC3-4D, the MAF1 deletion strain (Table 1). All four
suppressors were haploid maf1 mutants with additional
chromosomal suppressor mutations that gave a cold-sensitive phenotype.
The phenotype of R16 was the most severe since cell growth was
reduced at the permissive temperature. Mating of yeast containing
the suppressors to each other yielded cold-sensitive diploids,
indicating that all mutant alleles were members of a single
complementation group.
|
maf1
strains were performed. This indicates that a single nuclear locus was
responsible for the suppression effect. The cold-sensitive phenotype in
these strains segregated 2:2 in tetrads and was linked to
ade2-1. This linkage was further analyzed in a cross of
strain K2 with J12-5C (Table 1). Among 20 tetrads analyzed, 18 were PD
(parental ditype), indicating a 5-centimorgan (cM) genetic linkage of
ade2-1 and the cold-sensitive mutation (40).
Given our previous results identifying truncated forms of
RPC160 as a high-copy-number suppressor of
maf1-1, we hypothesized that the cold-sensitive suppressor
mutations recovered here map in RPC160, which is located
about 20 kbp from ADE2 on chromosome XV as indicated from
the yeast genome sequencing data. The physical distance between
RPC160 and ADE2 correlated well with a genetic
linkage of 5 cM (33). Indeed, introduction of a
centromeric plasmid carrying RPC160 complemented the
cold-sensitive growth of K2 and R16. These mapping and rescue data
indicated that the suppressor mutations are located in
RPC160.
The K2 suppressor mutant was back-crossed with a parental wild-type
strain to separate maf1-1 and rpc160 alleles by
meiosis. The cold-sensitive phenotype of MB156-1B rpc160-2
carrying the wild-type MAF1 (Table 1) was fully complemented
by pC160-6 centromeric plasmid encoding C160 (Fig. 3B). Total RNA
was isolated from rpc160-2 transformed with empty vector or
with plasmid-encoded C160. Examination of an ethidium-stained RNA gel
reveals that the rpc160-2 mutation leads to reduced levels
of tRNA (Fig. 3B).
Increased tRNA levels in maf1 mutants correlate with
increased tRNA synthesis rate in vitro.
The recovery of
RPC160 mutant alleles as suppressors of maf1-1
prompted us to investigate tRNA levels in maf1 mutants.
Total RNA was isolated from maf1-1 (MT6-7),
maf1 (KC3-4D), and the isogenic parental strains (T8-1D
and 11D, respectively) grown with a shift to the restrictive growth
conditions. Separation of total cellular RNAs by electrophoresis and
examination of ethidium-stained gels revealed a substantial increase of
tRNA levels in maf1-1 cells, whereas the levels of 5S and
5.85 rRNA remained stoichiometric and seemed to be unaffected by the
maf1-1 mutation (Fig. 4A).
|
maf1 strains (data not shown) the levels of
tRNAHis and tRNATyr were markedly elevated
compared to wild-type tRNA levels in the isogenic parental strains or
in a standard wild-type strain. This tRNA increase was detected
independently in two maf1 mutants (maf1-1 and
maf1) from different genetic backgrounds. Thus, it is
clear that the increase is due to the inactivation of Maf1p.
Quantification of the Northern blots revealed that maf1-1
cells have, respectively, (4.0 ± 0.2)- and (3.5 ± 0.1)-fold
elevated levels of tRNATyr and tRNAHis over
that of the wild-type when corrected for U3 snRNA content. Consistent
with the observations made with ethidium-stained RNA, Northern blots
showed no significant change of 5S rRNA level in maf1 versus
wild-type strain when U3 snRNA is taken as an internal control (Fig.
4B)
In accordance with the growth phenotype, the R16 (Fig. 4C) and K2 (data
not shown) cold-sensitive rpc160 suppressors reduce tRNA
levels in maf1 mutants. tRNATyr and
tRNAHis are reduced (5.0 ± 0.5)- and (8.2 ± 2.1)-fold, respectively, in R16 cells compared to maf1-1
cells without this suppressor (Fig. 4C). The reductions of
tRNATyr and tRNAHis by the K2 suppressor
mutation are, respectively, (2.1 ± 0.3)- and (2.5 ± 0.5)-fold (data not shown). Therefore, suppression of the Maf1p
deficiency by mutations in the C160 subunit of Pol III appears to be
correlated with a reduction of tRNA levels.
Since tRNA content is increased in maf1 mutant cells, we
determined whether the absence of functional Maf1p could increase tRNA
synthesis in vitro. We compared the transcription of SUP4 tDNATyr and tDNALeu3 in cellular extracts
prepared from maf1-1 and wild-type cells. We used crude
extracts so as to avoid removing Maf1p or putative components important
for Maf1p function in the wild-type samples. Radiolabeled transcripts
were analyzed by urea-PAGE, and the rate of tRNAs transcription was
monitored by quantitating the bands as described in Materials and
Methods. The relative transcription rates in wild-type and
maf1-1 extracts were estimated by reference to the
transcription of a mini-35S rRNA gene (a Pol I transcript) used as an
internal control. As shown in Fig. 5A,
there was a reproducible increase in the transcription rate of the two
tRNA genes in maf1-1 crude extracts (lanes 1 to 4). Means of
different transcription assays using five independent crude extracts
per strain and corrected for mini-35S rRNA levels established firmly the enhanced transcription rate of tRNA genes in crude extracts from
maf1-1 cells (Fig. 5B). Remarkably, the U6 snRNA and 5S rRNA were also reproducibly and significantly more actively transcribed in
maf1-1 extracts (Fig. 5A, lanes 5 to 8, and Fig. 5B),
suggesting that all class III genes could be affected by
maf1-1 to different extents.
|
|
Maf1p interacts with RNA Pol III. These genetic studies showed that the effect of Maf1p deficiency causing elevated tRNA levels is suppressed by alterations of C160. This genetic interaction suggested that Maf1p and Pol III might physically interact. Coimmunopurification experiments were therefore performed to investigate the possibility of a complex formation between Maf1p and RNA Pol III.
We constructed a strain expressing both C160 and Maf1p tagged with different epitopes. We used the strain MW671-HA (see Table 1) harboring a lethal
rpc160 deletion complemented by the HA-tagged RPC160 gene harbored on a centromeric plasmid
(14), and the chromosomal MAF1 gene in MW671-HA
was tagged with the sequence of 13 myc epitopes at its carboxyl
terminus (see Materials and Methods). The resulting strain, MW671-HA,
myc, which encodes two tagged proteins, Maf1p-myc and C160-HA, has a
wild-type phenotype with respect to MAF1 and
RPC160. The control strain, MW671-myc, codes for a tagged
Maf1p-myc and the untagged version of C160.
Extracts prepared from MW671-HA,myc, MW671-HA, and MW671-myc were
incubated with magnetic beads coated with anti-myc monoclonal antibody.
The beads were washed, and the bound proteins were eluted and analyzed
by SDS-PAGE, followed by immunoblotting. The anti-myc antibody revealed
a single band of about 70 kDa in extracts from MW671-HA,myc
(RPC160-HA MAF1-myc) and from MW671-myc
(MAF1-myc). This protein band was not observed in the
control extract from MW671-HA (RPC160-HA) (Fig.
7A, left panel) and therefore corresponds to Maf1p-myc, although the predicted molecular mass of the tagged protein was somewhat lower (65 kDa). Interestingly, a significant fraction (5 to 10%) of HA-tagged C160 was found to copurify with Maf1p-myc when the MW671-HA,myc (RPC160-HA MAF1-myc) extract
was incubated with anti-myc beads. The control immunopurified material from MW671-HA (RPC160-HA) cell extracts did not contain
Maf1p-myc nor C160-HA (Fig. 7A, left panel). These results suggested
the interaction of Maf1p and C160 subunit or at least the interaction of Maf1p and Pol III.
|
C82, C34, and AC40
were found to copurify with Maf1p
(Fig. 7B, left panel). These polypeptides were not detected in the
control extract from MW671-HA (RPC160-HA) cells subjected to
the anti-myc immunoprecipitation.
Note that the relative intensity of the immune complex in the Western
blots was similar when Pol III was directly immunopurified by anti-HA
antibody (Fig. 7B, right panel) or copurified with the myc-tagged Maf1p
(Fig. 7B, left). These results confirmed the associations of Maf1p and
Pol III. As determined by Western blot analysis, neither TBP nor
55,
95, and
131 subunits of TFIIIC copurified detectably with Maf1p.
A slight increase of Brf1/TFIIIB70 signal above background suggested
the possibility of a Maf1p-TFIIIB70 interaction (results not shown).
| |
DISCUSSION |
|---|
|
|
|---|
Regulation of Pol III-directed tRNA biosynthesis is a potentially important mechanism that may contribute to the cell metabolic economy and coordination of translation with growth. The genetic and biochemical data presented here support the model that in S. cerevisiae Maf1p is a negative effector of Pol III: (i) mutations in the MAF1 gene increased the level of tRNAs in vivo and the rate of Pol III RNA synthesis in vitro; (ii) Maf1p, a nuclear protein, coimmunopurified with the components of the Pol III complex; and (iii) mutations in the largest Pol III subunit, C160, suppressed mutations in MAF1 and restored normal levels of tRNA. The presence of proteins similar to yeast Maf1p in a wide variety of organisms suggests that Maf1p homologs may provide a mechanism for the coordination of Pol III transcription with cell growth rate in eukaryotes.
Pleiotropic phenotype of maf1 mutants.
maf1-1 was originally isolated as a mutation that decreases
the efficiency of the tRNA suppressor SUP11. Although one
might have anticipated that increased cellular tRNA levels would
improve the efficiency of tRNA-mediated nonsense suppression, our data show the opposite. There are a number of mechanisms that could account
for this counterintuitive result. First, since SUP11 tRNA is
a minor tRNA Tyr/UAA, even if SUP11 tRNA is proportionally elevated in the maf1 tRNA population, it may compete less
efficiently for tyrosyl-tRNA synthetase, EF1
, or ribosome binding,
resulting in the observed antisuppressor phenotype. This explanation is supported by the observation that increasing the copy number of a
SUP11 tRNA encoding gene overcomes the antisuppression of
maf1-1 cells (K. Pluta and M. Boguta, unpublished results).
Alternatively, reduced suppression could result from altered
SUP11 tRNA modification. We recently reported that cells
have limiting quantities of dimethylallyl pyrophosphate
(3), the precursor for the i6A modification
found at position 37 of tRNATyr. Since suppression is
dependent upon this modification and tRNAs are overproduced, it is
possible that not all i6A-containing tRNAs are completely
modified in maf1 cells. Our preliminary results indicate
that tRNAs in maf1-1 strains contain i6A (M. Boguta and N. C. Martin, unpublished results); nevertheless, partial modification would result in reduced nonsense suppression.
55, a TFIIIC subunit required
for tRNA transcription, impairs its function and cell growth at
elevated temperatures on nonfermentable carbon sources (32). Maf1p may be involved in coupling carbon metabolism
to tRNA transcription because the levels of tRNA in maf1-1
cells are fourfold increased on nonfermentable carbon source and only twofold increased on fermentable carbon source (data not shown).
Effect of Maf1p on Pol III transcription. Steady-state tRNA levels in maf1 mutants are significantly increased relative to 5S rRNA levels that reflect the cellular content in the 60S ribosomal subunit. Northern analysis confirmed that the level of two different tRNAs, tRNAHis and tRNATyr, increased about fourfold but the 5S rRNA level remained the same relative to U3 RNA that is a Pol II transcript. That result is supported by pulse-labeling experiments showing a threefold increase of tRNA synthesis in maf1-1 relative to 5.8S rRNA (Fig. 6). It is likely that the population of tRNAs was increased as a whole, as also suggested by the trailing of the tRNA species in ethidium bromide-stained stained gels (Fig. 4A).
Remarkably, in vitro mutant extracts showed a small but reproducible increase in tRNA synthesis and a larger effect on 5S rRNA, also a Pol III transcript. The fact that the in vitro synthesis rate but not the steady-state level of 5S rRNA in vivo is affected in the absence of functional Maf1p is intriguing. This result is reminiscent of the in vivo observation that mutations in essential components of the Pol III transcription system, including several Pol III subunits (C34, C31, C82, C55, and C160), caused a strong, preferential decline in tRNA synthesis, while 5S rRNA synthesis and the 5S rRNA/5.8S rRNA ratio remained relatively unaffected (18, 43). This observation is only partly understood (13). Since cell extracts from maf1-1 cells were found to be more active in transcribing several class III genes, including the 5S rRNA gene, in vitro, we suggest that the 5S rRNA made in excess of ribosome biogenesis needs is rapidly turned over.Interaction of Maf1p with RNA Pol III. The increased in vitro Pol III transcription of maf1-1 extracts suggests a direct interaction of Maf1p with the Pol III complex. The observation that mutations in the largest subunit of Pol III, C160, counteract MAF1 inactivation led us to investigate a possible physical interaction between Maf1p and Pol III. Immunopurification experiments demonstrated that Maf1p is directly or indirectly tightly associated with C160 in cell extracts. The precise binding target of Maf1p on Pol III, however, is undefined since C160 is part of a 17-subunit enzyme. That Maf1p is bound to Pol III and not to a hypothetical free pool of C160 polypeptides was confirmed by showing that three additional subunits of Pol III (C34, AC40, and C82) copurify, together with C160, with Maf1p. This finding strongly suggests that Maf1p represses tRNA synthesis by a direct action on the Pol III enzyme.
Maf1p might interfere with Pol III recruitment by the preinitiation TFIIIB-TFIIIC-DNA complex, or it might block a later stage of the transcription cycle or counteract a putative activator that might either be a component of the Pol III transcription machinery or an yet-as-unknown protein interacting with the Pol III enzyme. One could propose a model in which an undefined activator would bind to the N-terminal part of C160 to account for the fact that overexpression of that small part of C160 suppresses the maf1-1 defect, possibly by titrating the activator (6). Limitation of the activator would in consequence decrease the tRNA levels. The rpc160 cold-sensitive mutations could similarly interfere with the interaction or the function of the putative activator. Alternatively, these mutations could decrease the basal enzyme activity, thereby restoring a lower level of tRNA. This explanation is in keeping with the cryosensitive phenotype of the R16 and K2 suppressors but does not account well for the fact that all suppressor mutations isolated affected C160 and not other subunits of Pol III. It is interesting that stationary-phase cells, with repressed tRNA synthesis, have a normal in vivo footprinting pattern on the TFIIIB binding region and a decreased occupancy of the transcription start site (
10 to +15 region) indicative of a Pol III recruitment defect
(25). Our attempts to supplement Maf1p-deficient transcription extracts with recombinant Maf1p to restore control (decreased) levels of SUP4 DNA transcription were unsuccessful.
Maf1p, the founding member of a new class of Pol III negative
effectors.
There is a remarkable conservation of the yeast and
human Pol III machineries. The most conserved components are those
involved in transcription complex assembly: subunit of TFIIIC,
131,
all components of TFIIIB (TBP, Brf/TFIIIB70, and B"/TFIIIB90), and the
tetrad of Pol III-specific subunits (C82, C34, C31, and C17) all have
structural and functional homologs in human cells (2, 15, 24, 44,
50, 51). Since Maf1p is conserved across a wide range of
organisms, it is probable that the orthologs of Maf1p are involved in
Pol III regulation in higher cells. This would be very interesting in
light of the connection between Pol III regulation and the malignancy
process (29). The abundance of Pol III transcripts is
abnormally elevated in many types of transformed and tumor cells
(55). In mammals, two tumor suppressors, Rb
(53) and p53 (7, 9), act as global repressors
of Pol III transcription. Rb and p53 interact with and inactivate
TFIIIB (9, 10, 28). Remarkably, Rb mutations occurring in
tumors also release TFIIIB from repression (10).
Deregulation of the control of Pol III and Pol I transcription is
clearly an important step in tumor development. Therefore, it will be
important to determine whether Maf1p orthologs really represent a new
class of Pol III regulators in mammals.
| |
ACKNOWLEDGMENTS |
|---|
We thank B. Szczesniak and M. Steffen for excellent technical assistance. We are also grateful to Joël Acker, Christine Conesa, Gérald Peyroche, and Emmanuel Favry (CEA/Saclay) for helpful discussions and their help with the in vitro experiments.
This work was supported by State Committee for Scientific Research (KBN) grant 6PO4B02915 to K.P. and M.B., State Committee for Scientific Research grant 6P04A03315 to K.P. National Science Foundation grant MCB 9506810 to A.K.H., National Science Foundation grant MCB9528216 to N.C.M., and French-Polish Centre of Biotechnology of Plants grants to K.P. and W.J.S.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Genetics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawinskiego 5a, 02 106 Warsaw, Poland. Phone: (48 22)659-70-72, ext. 1312. Fax: (48)39121623. E-mail: magda{at}ibbrain.ibb.waw.pl.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 2. |
Arrebola, R.,
N. Manaud,
S. Rozenfeld,
M. C. Marsolier,
O. Lefebvre,
C. Carles,
P. Thuriaux,
C. Conesa, and A. Sentenac.
1998.
Tau91, an essential subunit of yeast transcription factor IIIC, cooperates with tau138 in DNA binding.
Mol. Cell. Biol.
18:1-9 |
| 3. |
Benko, A. L.,
G. Vaduva,
N. C. Martin, and A. K. Hopper.
2000.
Competition between a sterol biosynthetic enzyme and tRNA modification in addition to changes in the protein synthesis machinery causes altered nonsense suppression.
Proc. Natl. Acad. Sci. USA
97:61-66 |
| 4. | Boeke, J. D., F. Lacroute, and G. R. Fink. 1984. A positive selection for mutants lacking orotidine 5' phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Mol. Gen. Genet. 197:345-346[CrossRef][Medline]. |
| 5. |
Boguta, M.,
L. A. Hunter,
E. C. Gillman,
N. C. Martin, and A. K. Hopper.
1994.
Subcellular locations of MOD5 proteins: mapping of the sequences sufficient for targeting to mitochondria and demonstration that mitochondrial and nuclear isoforms commingle in the cytosol.
Mol. Cell. Biol.
14:2298-2306 |
| 6. | Boguta, M., K. Czerska, and T. Zoladek. 1997. Mutation in a new gene MAF1 affects tRNA suppressor efficiency in Saccharomyces cerevisiae. Gene 185:291-296[CrossRef][Medline]. |
| 7. | Cairns, C. A., and R. J. White. 1998. p53 is a general repressor of RNA polymerase III transcription. EMBO J. 17:3112-3123[CrossRef][Medline]. |
| 8. | Chedin, S., M. L. Ferri, G. Peyroche, J. C. Andrau, S. Jourdain, O. Lefebvre, M. Werner, C. Carl, and A. Sentenac. 1998. The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Cold Spring Harbor Symp. Quant. Biol. 63:381-389[CrossRef][Medline]. |
| 9. | Chesnokov, I., W. M. Chu, M. R. Botchan, and C. W. Schmid. 1996. p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner. Mol. Cell. Biol. 16:7084-7088[Abstract]. |
| 10. |
Chu, W. M.,
Z. Wang,
R. G. Roeder, and C. W. Schmid.
1997.
RNA polymerase III transcription repressed by Rb through its interactions with TFIII and TFIIIC2.
J. Biol. Chem.
272:14755-14761 |
| 11. |
Clarke, E. M.,
C. L. Peterson,
A. V. Brainard, and D. L. Riggs.
1996.
Regulation of the RNA polymerase I and III transcription systems in response to growth conditions.
J. Biol. Chem.
271:22189-22195 |
| 12. | Cullin, C., and L. Minvielle-Sebastia. 1994. Multipurpose vectors designed for the fast generation of N- or C-terminal epitope-tagged proteins. Yeast 10:105-112[CrossRef][Medline]. |
| 13. |
Dechampesme, A. M.,
O. Koroleva,
I. Leger-Silvestre,
N. Gas, and S. Camier.
1999.
Assembly of 5S ribosomal RNA is required at a specific step of the pre-rRNA processing pathway.
J. Cell Biol.
145:1369-1380 |
| 14. | Dieci, G., S. Herman-Le-Denmat, E. L. Lukhtanov, P. Thuriaux, M. Werner, and A. Sentenac. 1995. A universally conserved region of the largest subunit participates in the active site of RNA polymerase III. EMBO J. 14:3766-3776[Medline]. |
| 15. |
Ferri, M. L.,
G. Peyroche,
M. Siaut,
O. Lefebvre,
C. Carles,
C. Conesa, and A. Sentenac.
2000.
A novel subunit of yeast RNA polymerase III interacts with the TFIIB-related domain of TFIIIB70.
Mol. Cell. Biol.
20:488-495 |
| 16. | Gietz, R. D., and A. Sugino. 1988. New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene 74:527-534[CrossRef][Medline]. |
| 17. |
Gottesfeld, J. M.,
V. J. Wolf,
T. Dang,
D. J. Forbes, and P. Hartl.
1994.
Mitotic repression of RNA polymerase III transcription in vitro mediated by phosphorylation of a TFIIIB component.
Science
263:81-84 |
| 18. |
Gudenus, R.,
S. Mariotte,
A. Moenne,
A. Ruet,
S. Memet,
J. M. Buhler,
A. Sentenac, and P. Thuriaux.
1988.
Conditional mutants of RPC160, the gene encoding the largest subunit of RNA polymerase C in Saccharomyces cerevisiae.
Genetics
119:517-526 |
| 19. |
Henikoff, S., and J. G. Henikoff.
1992.
Amino acid substitution matrices from protein blocks.
Proc. Natl. Acad. Sci. USA
89:10915-10919 |
| 20. | Hoeffler, W. K., R. Kovelman, and R. G. Roeder. 1988. Activation of transcription factor IIIC by the adenovirus E1A protein. Cell 53:907-920[CrossRef][Medline]. |
| 21. |
Hofmann, K.,
P. Bucher,
L. Falquet, and A. Bairoch.
1999.
The PROSITE database, its status in 1999.
Nucleic Acids Res.
27:215-219 |
| 22. | Hopper, A. K. 1990. Genetic methods for study of trans-acting genes involved in processing of precursors to yeast cytoplasmic transfer RNAs. Methods Enzymol. 181:400-420[Medline]. |
| 23. | Huet, J., N. Manaud, G. Dieci, G. Peyroche, C. Conesa, O. Lefebvre, A. Ruet, M. Riva, and A. Sentenac. 1996. RNA polymerase III and class III transcription factors from Saccharomyces cerevisiae. Methods Enzymol. 273:249-267[Medline]. |
| 24. |
Hsieh, Y. J.,
Z. Wang,
R. Kovelman, and R. G. Roeder.
1999.
Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III.
Mol. Cell. Biol.
19:4944-4952 |
| 25. |
Huibregtse, J. M., and D. R. Engelke.
1989.
Genomic footprinting of a yeast tRNA gene reveals stable complexes over the 5'-flanking region.
Mol. Cell. Biol.
9:3244-3252 |
| 26. | Kaiser, C., S. Michaelis, and A. Mitchel. 1994. Yeast RNA isolation: methods in yeast genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 27. |
Kief, D. R., and J. R. Warner.
1981.
Coordinate control of syntheses of ribosomal ribonucleic acid and ribosomal proteins during nutritional shift-up in Saccharomyces cerevisiae.
Mol. Cell. Biol.
1:1007-1015 |
| 28. | Larminie, C. G., C. A. Cairns, R. Mital, K. T. Martin, K. Kouzarides, S. P. Jackson, and R. J. White. 1997. Mechanistic analysis of RNA polymerase III regulation by the retinoblastoma protein. EMBO J. 16:2061-2071[CrossRef][Medline]. |
| 29. | Larminie, C. G., H. M. Alzuherri, C. A. Cairns, A. McLees, and R. J. White. 1998. Transcription by RNA polymerases I and III: a potential link between cell growth, protein synthesis and the retinoblastoma protein. J. Mol. Med. 76:94-103[CrossRef][Medline]. |
| 30. | Li, Y., R. D. Moir, I. K. Sethy-Coraci, J. R. Warner, and I. M. Willis. 2000. Repression of ribosome and tRNA synthesis in secretion-defective cells is signaled by a novel branch of the cell integrity pathway. Mol. Cell. Biol. 11:3843-3851. |
| 31. | Longtine, M. S., A. McKenzie III, D. J. Demarini, N. G. Shah, A. Wach, A. Brachat, P. Philippsen, and J. R. Pringle. 1998. Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast 14:953-961[CrossRef][Medline]. |
| 32. |
Manaud, N.,
R. Arrebola,
B. Buffin-Meyer,
O. Lefebvre,
H. Voss,
M. Riva,
C. Conesa, and A. Sentenac.
1998.
A chimeric subunit of yeast transcription factor IIIC forms a subcomplex with tau95.
Mol. Cell. Biol.
18:3191-3200 |
| 33. | Mortimer, R. K., D. Schild, C. R. Contopoulou, and J. A. Kans. 1989. Genetic map of Saccharomyces cerevisiae, 10th Yeast 5:321-403[CrossRef][Medline]. |
| 34. | Murawski, M., B. Szczesniak, T. Zoladek, A. K. Hopper, N. C. Martin, and M. Boguta. 1994. maf1 mutation alters the subcellular localization of the Mod5 protein in yeast. Acta Biochim. Pol. 41:441-448[Medline]. |
| 35. |
Musters, W.,
J. Knol,
P. Maas,
A. F. Dekker, and H. Van Heerikhuizen.
1989.
Linker scanning of the yeast RNA polymerase I promoter.
Nucleic Acids Res.
17:9661-9678 |
| 36. | Oliver, S. G., and C. S. McLaughlin. 1977. The regulation of RNA synthesis in yeast. I: Starvation experiments. Mol. Gen. Genet. 154:145-153[CrossRef][Medline]. |
| 37. | Pringle, J. R., A. E. Adams, D. R. Drubin, and B. K. Haarer. 1991. Immunofluorescence methods for yeast. Methods Enzymol. 194:565-602[Medline]. |
| 38. |
Riggs, D. L., and M. Nomura.
1990.
Specific transcription of Saccharomyces cerevisiae 35 S rDNA by RNA polymerase I in vitro.
J. Biol. Chem.
265:7596-7603 |
| 39. |
Sethy, I.,
R. D. Moir,
M. Librizzi, and I. M. Willis.
1995.
In vitro evidence for growth regulation of tRNA gene transcription in yeast. A role for transcription factor (TF) IIIB70 and TFIIIC.
J. Biol. Chem.
270:28463-28470 |
| 40. | Sherman, F., and P. Wakem. 1991. Mapping of the yeast genes. Methods Enzymol. 194:38-56[Medline]. |
| 41. |
Shulman, R. W.,
C. E. Sripati, and J. R. Warner.
1977.
Noncoordinated transcription in the absence of protein synthesis in yeast.
J. Biol. Chem.
252:1344-1349 |
| 42. |
Sinn, E.,
Z. Wang,
R. Kovelman, and R. G. Roeder.
1995.
Cloning and characterization of a TFIIIC2 subunit (TFIIIC beta) whose presence correlates with activation of RNA polymerase III-mediated transcription by adenovirus E1A expression and serum factors.
Genes Dev.
9:675-685 |
| 43. |
Stettler, S.,
S. Mariotte,
M. Riva,
A. Sentenac, and P. Thuriaux.
1992.
An essential and specific subunit of RNA polymerase III (C) is encoded by gene RPC34 in Saccharomyces cerevisiae.
J. Biol. Chem.
267:21390-21395 |
| 44. | Teichmann, M., G. Dieci, J. Huet, J. Ruth, A. Sentenac, and K. H. Seifart. 1997. Functional interchangeability of TFIIIB components from yeast and human cells in vitro. EMBO J. 16:4708-4716[CrossRef][Medline]. |
| 45. |
Thompson, J. D.,
T. J. Plewniak,
F. Jeanmougin, and D. G. Higgins.
1997.
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.
Nucleic Acids Res.
25:4876-4882 |
| 46. |
Tower, J., and B. Sollner-Webb.
1988.
Polymerase III transcription factor B activity is reduced in extracts of growth-restricted cells.
Mol. Cell. Biol.
8:1001-1005 |
| 47. | Tyers, M., G. Tokiwa, and B. Futcher. 1993. Comparison of the Saccharomyces cerevisiae G1 cyclins: Cln3 may be an upstream activator of Cln1, Cln2 and other cyclins. EMBO J. 12:1955-1968[Medline]. |
| 48. | Waldron, C. 1977. Synthesis of ribosomal and transfer ribonucleic acids in yeast during a nutritional shift-up. J. Gen. Microbiol. 98:215-221[Medline]. |
| 49. |
Waldron, C., and F. Lacroute.
1975.
Effect of growth rate on the amounts of ribosomal and transfer ribonucleic acids in yeast.
J. Bacteriol.
122:855-865 |
| 50. |
Wang, Z.,
T. Luo, and R. G. Roeder.
1997.
Identification of an autonomously initiating RNA polymerase III holoenzyme containing a novel factor that is selectively inactivated during protein synthesis inhibition.
Genes Dev.
11:2371-2382 |
| 51. |
Wang, Z., and R. G. Roeder.
1997.
Three human RNA polymerase III-specific subunits form a subcomplex with a selective function in specific transcription initiation.
Genes Dev.
11:1315-1326 |
| 52. | White, R. J., D. Stott, and P. W. Rigby. 1989. Regulation of RNA polymerase III transcription in response to F9 embryonal carcinoma stem cell differentiation. Cell 59:1081-1092[CrossRef][Medline]. |
| 53. | White, R. J., D. Trouche, K. Martin, S. P. Jackson, and T. Kouzarides. 1996. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature 382:88-90[CrossRef][Medline]. |
| 54. | White, R. J. 1997. Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control? Trends Biochem. Sci. 22:77-80[CrossRef][Medline]. |
| 55. | White, R. J. 1998. RNA polymerase III transcription. Springer-Verlag/ R. G. Landes Co., New York, N.Y. |
| 56. | Zoladek, T., G. Vaduva, L. A. Hunter, M. Boguta, B. D. Go, N. C. Martin, and A. K. Hopper. 1995. Mutants altering the mitochondrial-cytoplasmic distribution of Mod5p implicate the actin cytoskeleton and mRNA 3' ends and/or protein synthesis in mitochondrial delivery. Mol. Cell. Biol. 15:6884-6894[Abstract]. |
This article has been cited by other articles: